Stock Warrant
WARRANTenGene Therapeutics Inc. Warrants
No redemption notice detected. Our weekly 8-K watcher runs every Friday and stamps this card if the issuer files a redemption 8-K.
ENGNW is enGene Therapeutics Inc. Warrants (Healthcare) — a non-dividend-paying stock. Trading at $0.23. Capital Quality Rank: 49/100 — Stagnant mediocrity.
Stock snapshot
| Price | $0.23 |
| Market cap | — |
| Sector | Healthcare |
| Exchange | — |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 49 / 100 · Stagnant mediocrity |
| ROIC (TTM) | -17.1% |
| Shareholder buyback yield | 0.00% |
| Altman Z-score zone | Distress |
About ENGNW
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
Related non-dividend companies
Other non-dividend stocks investors research alongside ENGNW. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is ENGNW's current stock price?
ENGNW (enGene Therapeutics Inc. Warrants) is currently trading at $0.23.
Does ENGNW pay a dividend?
ENGNW (enGene Therapeutics Inc. Warrants) does not currently pay a regular dividend.
What is ENGNW's Capital Quality Rank?
ENGNW has a Capital Quality Rank of 49/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track ENGNW in DiviDrip
Add ENGNW to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search ENGNW and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-08-23. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.